Recall Register

Drug recall: Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals…

Class II FDA enforcement event 100038. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Brandywine Pharmaceuticals, LLC started this drug recall on 6 Oct 2026. The firm address in the FDA record is in West Chester, PA. FDA put the recall in Class II. FDA event 100038 has 2 product records. The first FDA enforcement report date is 4 Nov 2026. The record gives the status Ongoing. 50 of the 281 drug events that started in 2026 have more product records. The median drug event of 2026 has 1 product record.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide within U.S

Recalling firm

Brandywine Pharmaceuticals, LLC, West Chester, PA.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

2 product records in the event.

FDA event 100038: product records
Recall numberProductQuantityClassStatusReport date
D-0110-2027Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-101,620 100-count bottlesClass IIOngoing4 Nov 2026
D-0111-2027Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.1,332 100-count bottlesClass IIOngoing4 Nov 2026

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2026
281
Share of these events in Class II
75%
Product records in this event
2
Events of the firm on the register
1

Official channels

Cite this page

Recall Register. FDA enforcement event 100038. https://recallregister.com/fda/ii/100038/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
10 Nov 2026
Newest FDA report date on the register
4 Nov 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide within U.S
What quantity of product is in FDA event 100038?
The event has 2 product records. The first record gives this quantity: 1,620 100-count bottles
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2026 have the same class?
75% of the 281 drug events that started in 2026 are in Class II.